Cleared Traditional

K182320 - BD Contoured Base Pen Needle

K182320 is an FDA 510(k) clearance for BD Contoured Base Pen Needle, manufactured by Becton, Dickinson and Company. The device is a Class 2 General Hospital device with product code FMI cleared through the Traditional 510(k) pathway after a 115-day FDA review.

K182320 · Becton, Dickinson and Company · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2018
Decision
115d
Days
Class 2
Risk

K182320 is an FDA 510(k) clearance for the BD Contoured Base Pen Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Becton, Dickinson and Company (Franklin Lakes, US). The FDA issued a Cleared decision on December 20, 2018 after a review of 115 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Becton, Dickinson and Company devices

FDA 510(k) Submission Details - K182320

510(k) Number K182320 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 27, 2018
Decision Date December 20, 2018
Days to Decision 115 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
14d faster than avg
Panel avg: 129d · This submission: 115d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FMI Device Classification - Class 2, Special Controls

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 271
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K182320.
Safety insulin needle for single use
K181447 · Berpu Medical Technology Co., Ltd. · Mar 2019
BD Vacutainer Eclipse UltraFill Blood Collection Needle
K181730 · Becton, Dickinson and Company · Mar 2019
U&U Blood Collection Sets
K181508 · U&U Medical Technology Co, Ltd. · Feb 2019
Sol-M Blood Collection Needles, Sol-Care Safety Blood Collection Needles, Sol-Care Safety Blood Collection Needle with Holders, Sol-M Blood Collection Set
K182146 · Sol-Millennium Medical, Inc. · Dec 2018
Immucise Intradermal Injection System
K181369 · Terumo Corporation · Nov 2018
EZ-IO Intraosseous Vascular Access System
K180395 · Arrow International, Inc. (Subsidiary of Teleflex, Inc.) · Nov 2018